Neuroendocrine Carcinoma Market 2027 By Indication Type, Treatment Type, End User | The Insight Partners

Neuroendocrine Carcinoma Market to 2027 - Global Analysis and Forecasts by Indication Type (Gastric Neuroendocrine Tumor, Lung Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors) ; Treatment Type (Chemotherapy, Antimetabolites, Alkylating agents, Natural Products, Targeted Therapy, Tyrosine Kinase Inhibitor, mTOR Inhibitor, Somatostatin Analogs) ; End User (Hospitals, Clinics, Oncology Centers, Ambulatory Surgical Centers)

Report Code: TIPRE00005798 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Neuroendocrine Carcinoma is a kind of tumor that begins in the hormone producing cells of the neuroendocrine systems made up of the endocrine system and nervous system. These neuroendocrine cells are found throughout the body including kidneys, intestines, stomach etc. some common symptoms of neuroendocrine carcinoma are hyperglycemia, weight loss, jaundice, fever, anxiety, headache etc.

MARKET DYNAMICS
The Neuroendocrine Carcinoma market is anticipated to grow in the forecast, owing to the factors such as rising demand of neuroendocrine carcinoma, growing number of clinical trials, exploration of new generation sequencing technologies, increasing partnership to strengthen product portfolios, increasing r&d investments and quick regulatory approvals. Nevertheless, high cost of the treatment is expected to hamper the growth of market during the forecast period.

MARKET SCOPE
The "Global Neuroendocrine Carcinoma Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Neuroendocrine Carcinoma market with detailed market segmentation by indication type, treatment type, end user and geography. The global Neuroendocrine Carcinoma market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Neuroendocrine Carcinoma market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Neuroendocrine Carcinoma market is segmented on the basis of indication type, treatment type and end user. Based on indication type the market is segmented into Gastric Neuroendocrine Tumor, Lung Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors. Based on treatment type the market is segmented into Chemotherapy, Antimetabolites, Alkylating agents, Natural Products, Targeted Therapy, Tyrosine Kinase Inhibitor, mTOR Inhibitor, Somatostatin Analogs. Based on end user the market is segmented into Hospitals, Clinics, Oncology Centers, Ambulatory Surgical Centers.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Neuroendocrine Carcinoma market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Neuroendocrine Carcinoma market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Neuroendocrine Carcinoma market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Neuroendocrine Carcinoma market in these regions.

MARKET PLAYERS
The reports cover key developments in the Neuroendocrine Carcinoma market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Neuroendocrine Carcinoma market are anticipated to lucrative growth opportunities in the future with the rising demand for Neuroendocrine Carcinoma market in the global market. Below mentioned is the list of few companies engaged in the Neuroendocrine Carcinoma market.

The report also includes the profiles of Neuroendocrine Carcinoma market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Novartis AG
  • LEXICON PHARMACEUTICALS, INC
  • Amgen Inc
  • AbbVie Inc
  • Ipsen Pharma
  • Mateon Therapeutics, Inc
  • Mallinckrodt
  • CELGENE CORPORATION
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neuroendocrine Carcinoma Market - By Indication Type
1.3.2 Neuroendocrine Carcinoma Market - By Treatment Type
1.3.3 Neuroendocrine Carcinoma Market - By End User
1.3.4 Neuroendocrine Carcinoma Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NEUROENDOCRINE CARCINOMA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NEUROENDOCRINE CARCINOMA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NEUROENDOCRINE CARCINOMA MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROENDOCRINE CARCINOMA - GLOBAL MARKET OVERVIEW
6.2. NEUROENDOCRINE CARCINOMA - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NEUROENDOCRINE CARCINOMA MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION TYPE
7.1. OVERVIEW
7.2. INDICATION TYPE MARKET FORECASTS AND ANALYSIS
7.3. GASTRIC NEUROENDOCRINE TUMOR
7.3.1. Overview
7.3.2. Gastric Neuroendocrine Tumor Market Forecast and Analysis
7.4. LUNG NEUROENDOCRINE TUMORS
7.4.1. Overview
7.4.2. Lung Neuroendocrine Tumors Market Forecast and Analysis
7.5. PANCREATIC NEUROENDOCRINE TUMORS
7.5.1. Overview
7.5.2. Pancreatic Neuroendocrine Tumors Market Forecast and Analysis
7.6. APPENDICEAL NEUROENDOCRINE TUMORS
7.6.1. Overview
7.6.2. Appendiceal Neuroendocrine Tumors Market Forecast and Analysis
8. NEUROENDOCRINE CARCINOMA MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT TYPE
8.1. OVERVIEW
8.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
8.3. CHEMOTHERAPY
8.3.1. Overview
8.3.2. Chemotherapy Market Forecast and Analysis
8.4. ANTIMETABOLITES
8.4.1. Overview
8.4.2. Antimetabolites Market Forecast and Analysis
8.5. ALKYLATING AGENTS
8.5.1. Overview
8.5.2. Alkylating agents Market Forecast and Analysis
8.6. NATURAL PRODUCTS
8.6.1. Overview
8.6.2. Natural Products Market Forecast and Analysis
8.7. TARGETED THERAPY
8.7.1. Overview
8.7.2. Targeted Therapy Market Forecast and Analysis
8.8. TYROSINE KINASE INHIBITOR
8.8.1. Overview
8.8.2. Tyrosine Kinase Inhibitor Market Forecast and Analysis
8.9. MTOR INHIBITOR
8.9.1. Overview
8.9.2. mTOR Inhibitor Market Forecast and Analysis
8.10. SOMATOSTATIN ANALOGS
8.10.1. Overview
8.10.2. Somatostatin Analogs Market Forecast and Analysis
9. NEUROENDOCRINE CARCINOMA MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. ONCOLOGY CENTERS
9.5.1. Overview
9.5.2. Oncology Centers Market Forecast and Analysis
9.6. AMBULATORY SURGICAL CENTERS.
9.6.1. Overview
9.6.2. Ambulatory Surgical Centers. Market Forecast and Analysis
10. NEUROENDOCRINE CARCINOMA MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Neuroendocrine Carcinoma Market Overview
10.1.2 North America Neuroendocrine Carcinoma Market Forecasts and Analysis
10.1.3 North America Neuroendocrine Carcinoma Market Forecasts and Analysis - By Indication Type
10.1.4 North America Neuroendocrine Carcinoma Market Forecasts and Analysis - By Treatment Type
10.1.5 North America Neuroendocrine Carcinoma Market Forecasts and Analysis - By End User
10.1.6 North America Neuroendocrine Carcinoma Market Forecasts and Analysis - By Countries
10.1.6.1 United States Neuroendocrine Carcinoma Market
10.1.6.1.1 United States Neuroendocrine Carcinoma Market by Indication Type
10.1.6.1.2 United States Neuroendocrine Carcinoma Market by Treatment Type
10.1.6.1.3 United States Neuroendocrine Carcinoma Market by End User
10.1.6.2 Canada Neuroendocrine Carcinoma Market
10.1.6.2.1 Canada Neuroendocrine Carcinoma Market by Indication Type
10.1.6.2.2 Canada Neuroendocrine Carcinoma Market by Treatment Type
10.1.6.2.3 Canada Neuroendocrine Carcinoma Market by End User
10.1.6.3 Mexico Neuroendocrine Carcinoma Market
10.1.6.3.1 Mexico Neuroendocrine Carcinoma Market by Indication Type
10.1.6.3.2 Mexico Neuroendocrine Carcinoma Market by Treatment Type
10.1.6.3.3 Mexico Neuroendocrine Carcinoma Market by End User
10.2. EUROPE
10.2.1 Europe Neuroendocrine Carcinoma Market Overview
10.2.2 Europe Neuroendocrine Carcinoma Market Forecasts and Analysis
10.2.3 Europe Neuroendocrine Carcinoma Market Forecasts and Analysis - By Indication Type
10.2.4 Europe Neuroendocrine Carcinoma Market Forecasts and Analysis - By Treatment Type
10.2.5 Europe Neuroendocrine Carcinoma Market Forecasts and Analysis - By End User
10.2.6 Europe Neuroendocrine Carcinoma Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Neuroendocrine Carcinoma Market
10.2.6.1.1 Germany Neuroendocrine Carcinoma Market by Indication Type
10.2.6.1.2 Germany Neuroendocrine Carcinoma Market by Treatment Type
10.2.6.1.3 Germany Neuroendocrine Carcinoma Market by End User
10.2.6.2 France Neuroendocrine Carcinoma Market
10.2.6.2.1 France Neuroendocrine Carcinoma Market by Indication Type
10.2.6.2.2 France Neuroendocrine Carcinoma Market by Treatment Type
10.2.6.2.3 France Neuroendocrine Carcinoma Market by End User
10.2.6.3 Italy Neuroendocrine Carcinoma Market
10.2.6.3.1 Italy Neuroendocrine Carcinoma Market by Indication Type
10.2.6.3.2 Italy Neuroendocrine Carcinoma Market by Treatment Type
10.2.6.3.3 Italy Neuroendocrine Carcinoma Market by End User
10.2.6.4 Spain Neuroendocrine Carcinoma Market
10.2.6.4.1 Spain Neuroendocrine Carcinoma Market by Indication Type
10.2.6.4.2 Spain Neuroendocrine Carcinoma Market by Treatment Type
10.2.6.4.3 Spain Neuroendocrine Carcinoma Market by End User
10.2.6.5 United Kingdom Neuroendocrine Carcinoma Market
10.2.6.5.1 United Kingdom Neuroendocrine Carcinoma Market by Indication Type
10.2.6.5.2 United Kingdom Neuroendocrine Carcinoma Market by Treatment Type
10.2.6.5.3 United Kingdom Neuroendocrine Carcinoma Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Neuroendocrine Carcinoma Market Overview
10.3.2 Asia-Pacific Neuroendocrine Carcinoma Market Forecasts and Analysis
10.3.3 Asia-Pacific Neuroendocrine Carcinoma Market Forecasts and Analysis - By Indication Type
10.3.4 Asia-Pacific Neuroendocrine Carcinoma Market Forecasts and Analysis - By Treatment Type
10.3.5 Asia-Pacific Neuroendocrine Carcinoma Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Neuroendocrine Carcinoma Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Neuroendocrine Carcinoma Market
10.3.6.1.1 Australia Neuroendocrine Carcinoma Market by Indication Type
10.3.6.1.2 Australia Neuroendocrine Carcinoma Market by Treatment Type
10.3.6.1.3 Australia Neuroendocrine Carcinoma Market by End User
10.3.6.2 China Neuroendocrine Carcinoma Market
10.3.6.2.1 China Neuroendocrine Carcinoma Market by Indication Type
10.3.6.2.2 China Neuroendocrine Carcinoma Market by Treatment Type
10.3.6.2.3 China Neuroendocrine Carcinoma Market by End User
10.3.6.3 India Neuroendocrine Carcinoma Market
10.3.6.3.1 India Neuroendocrine Carcinoma Market by Indication Type
10.3.6.3.2 India Neuroendocrine Carcinoma Market by Treatment Type
10.3.6.3.3 India Neuroendocrine Carcinoma Market by End User
10.3.6.4 Japan Neuroendocrine Carcinoma Market
10.3.6.4.1 Japan Neuroendocrine Carcinoma Market by Indication Type
10.3.6.4.2 Japan Neuroendocrine Carcinoma Market by Treatment Type
10.3.6.4.3 Japan Neuroendocrine Carcinoma Market by End User
10.3.6.5 South Korea Neuroendocrine Carcinoma Market
10.3.6.5.1 South Korea Neuroendocrine Carcinoma Market by Indication Type
10.3.6.5.2 South Korea Neuroendocrine Carcinoma Market by Treatment Type
10.3.6.5.3 South Korea Neuroendocrine Carcinoma Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Neuroendocrine Carcinoma Market Overview
10.4.2 Middle East and Africa Neuroendocrine Carcinoma Market Forecasts and Analysis
10.4.3 Middle East and Africa Neuroendocrine Carcinoma Market Forecasts and Analysis - By Indication Type
10.4.4 Middle East and Africa Neuroendocrine Carcinoma Market Forecasts and Analysis - By Treatment Type
10.4.5 Middle East and Africa Neuroendocrine Carcinoma Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Neuroendocrine Carcinoma Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Neuroendocrine Carcinoma Market
10.4.6.1.1 South Africa Neuroendocrine Carcinoma Market by Indication Type
10.4.6.1.2 South Africa Neuroendocrine Carcinoma Market by Treatment Type
10.4.6.1.3 South Africa Neuroendocrine Carcinoma Market by End User
10.4.6.2 Saudi Arabia Neuroendocrine Carcinoma Market
10.4.6.2.1 Saudi Arabia Neuroendocrine Carcinoma Market by Indication Type
10.4.6.2.2 Saudi Arabia Neuroendocrine Carcinoma Market by Treatment Type
10.4.6.2.3 Saudi Arabia Neuroendocrine Carcinoma Market by End User
10.4.6.3 U.A.E Neuroendocrine Carcinoma Market
10.4.6.3.1 U.A.E Neuroendocrine Carcinoma Market by Indication Type
10.4.6.3.2 U.A.E Neuroendocrine Carcinoma Market by Treatment Type
10.4.6.3.3 U.A.E Neuroendocrine Carcinoma Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Neuroendocrine Carcinoma Market Overview
10.5.2 South and Central America Neuroendocrine Carcinoma Market Forecasts and Analysis
10.5.3 South and Central America Neuroendocrine Carcinoma Market Forecasts and Analysis - By Indication Type
10.5.4 South and Central America Neuroendocrine Carcinoma Market Forecasts and Analysis - By Treatment Type
10.5.5 South and Central America Neuroendocrine Carcinoma Market Forecasts and Analysis - By End User
10.5.6 South and Central America Neuroendocrine Carcinoma Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Neuroendocrine Carcinoma Market
10.5.6.1.1 Brazil Neuroendocrine Carcinoma Market by Indication Type
10.5.6.1.2 Brazil Neuroendocrine Carcinoma Market by Treatment Type
10.5.6.1.3 Brazil Neuroendocrine Carcinoma Market by End User
10.5.6.2 Argentina Neuroendocrine Carcinoma Market
10.5.6.2.1 Argentina Neuroendocrine Carcinoma Market by Indication Type
10.5.6.2.2 Argentina Neuroendocrine Carcinoma Market by Treatment Type
10.5.6.2.3 Argentina Neuroendocrine Carcinoma Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. NEUROENDOCRINE CARCINOMA MARKET, KEY COMPANY PROFILES
12.1. F. HOFFMANN-LA ROCHE LTD
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. LEXICON PHARMACEUTICALS, INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. AMGEN INC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ABBVIE INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. IPSEN PHARMA
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MATEON THERAPEUTICS, INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MALLINCKRODT
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. CELGENE CORPORATION
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

- F. Hoffmann-La Roche Ltd
- Pfizer Inc
- Novartis AG
- LEXICON PHARMACEUTICALS, INC
- Amgen Inc
- AbbVie Inc
- Ipsen Pharma
- Mateon Therapeutics, Inc
- Mallinckrodt
- CELGENE CORPORATION